Godavari's ₹17-Crore ENA Trap: When GST Classification Threatens Margins
A regulatory show cause notice on ENA supply classification exposes material cash-flow and margin risk as the company already slides into quarterly losses.
₹244.25
as of Aug 21, 2026
MID-CAP
₹227 – ₹353
30.8% below ATH
~₹1,250 Cr
5.12 Cr shares
Regulatory Filing & Material Exposure
₹17 Cr GST Demand on ENA Supply Classification
Godavari Biorefineries received a show cause notice from the Central GST authority demanding ₹17.02 crore in GST on Extra Neutral Alcohol (ENA) supplies to Karnataka State Beverages Corporation Ltd. (KSBCL) during 2021-22 to October 2024. The company classified these supplies as 'exempted supply' and did not collect GST; the tax authority disputes this classification and claims GST liability of approximately ₹8.51 crore CGST and ₹8.51 crore SGST.
Read:This is not a minor filing. The ₹17-crore demand represents ~3% of the company's annualized revenue (₹560 Cr in Q1 FY27) and threatens both near-term cash flow and working capital. If upheld in appeals, the company must pay the demand. The timing is critical: Godavari posted a loss of ₹19.3 crore in Q1 FY27, down sharply from ₹52.9 crore profit in Q4 FY26. Adding a ₹17-crore contingent liability to deteriorating earnings creates material downside risk.
BSE FilingThe ENA classification dispute is not academic. KSBCL is a major state-owned buyer of neutral alcohol for beverage production. Godavari's attempt to supply under an 'exempted' GST classification — likely assuming industrial/commercial exemption — now faces direct challenge by the tax authority. The key technical question: does ENA for alcoholic-beverage production qualify as exempt? Historically, industrial ethanol has faced classification ambiguity. The ₹17-crore demand suggests the tax authority views it as taxable supply, period.
Margin Collapse and Loss Trajectory
Godavari's margin deterioration is dramatic and recent. In Q4 FY26 (Jan–Mar 2026), the company reported consolidated revenues of ₹570 crore and a net profit of ₹52.88 crore — a 9.28% margin and strongly positive EBITDA. Fast forward one quarter to Q1 FY27 (Apr–Jun 2026), and the picture inverts: revenues of ₹559.9 crore, net loss of ₹19.3 crore, and negative 3.45% margin. EBITDA cratered from ₹41.66 crore to ₹2.6 crore — a drop of ~94%. The quarterly swing is severe enough to suggest operational headwinds beyond ENA (commission of a 200 KLPD grain-based distillery, input cost pressure), but the GST demand adds an unresolved tail risk to an already fragile quarter.
The GST demand creates a double squeeze: on the liability side (if upheld, ₹17 crore cash outflow), and on investor sentiment (regulatory uncertainty + operational softness = multiple compression). Godavari is trading 30% below its 52-week high of ₹353; volume has declined sharply from 594k shares/day (20-day avg) to 148k (5-day avg), suggesting reduced institutional interest.
Price Action & Technical Setup
42.2
244.25
- Above SMA20 (₹257)
- Above SMA50 (₹269)
- Above SMA200 (₹279)
The technicals paint a downtrend: price below all key moving averages, RSI at 42.2 (neutral, leaning soft), and volume contracting sharply. Support sits at ₹239; resistance at ₹284. The stock has already repriced ~31% from its December 2025 peak, and recent data flow (Q1 loss + GST demand) suggests further wariness until the GST dispute shows legal clarity.
Revenue Resilience, Margin Crisis
Consolidated basis. EBITDA decline driven by elevated operating expenses, finance costs, and likely one-time/capacity-ramp charges from the 200 KLPD distillery commissioned in Q1.
Revenue held flat (~₹560 Cr annualized), but profitability collapsed. The ₹39-crore profit-to-loss swing is extraordinary and suggests either transient distillery ramp costs or structural margin pressure from input inflation and competitive intensity in the ethanol/FMCG space. The GST demand, if settled unfavorably, would clip a further ₹17 crore from earnings or balance-sheet equity.
What Happens Next
Three variables matter:
- 1
GST Show Cause Response
AwaitedGodavari must file a detailed response to the tax authority within 30 days (likely by late September 2026). The company's legal strategy—settlement, compromise, or full appeal—will clarify risk. A settlement at 50% of demand (~₹8.5 Cr) is not uncommon in classification disputes; full liability would hit hard.
- 2
Q2 FY27 Results
AwaitedEarnings on October 2026 will show whether the distillery ramp is normalizing margins or whether headwinds persist. If Q2 repeats Q1's loss, confidence in the business deteriorates further and the GST liability becomes a larger percentage of book value.
- 3
KSBCL Relationship
MonitorDoes the GST dispute rupture Godavari's supply contract with KSBCL, a state-owned anchor customer? Retention of KSBCL volume is critical to revenue stability. Any supply disruption would be a secondary shock.
The Case for Caution
The risk-reward tilts unfavorably near-term. On the downside: GST demand (₹17 Cr tail risk), operational losses (₹19 Cr Q1 loss, EBITDA down 94%), volume contraction, and technical weakness all argue for patience. On the upside: the distillery ramp-up could normalize margins in H2 FY27, the European patent for anti-cancer compounds offers a speculative upside, and the stock's 31% fall from ATH may be pricing in worst-case already. However, the confluence of regulatory uncertainty, profitability crisis, and deteriorating technicals suggests that downside (to ₹200–220) is more probable than upside until GST clarity and Q2 results arrive.
gst_response
GST Show Cause Response (Sep 2026): Company's legal defense and settlement intent.
q2_results
Q2 FY27 Earnings (Oct 2026): Distillery normalization and margin recovery trajectory.
cmp_support
Support at ₹239: Break below opens ₹200–210 zone. Hold above ₹245 to suggest stabilization.
volume
Trading Volume: Volume collapse signals institutional caution. Recovery >400k shares/day would suggest renewed appetite.
The data indicates material downside risk for Godavari Biorefineries over the next two to three quarters. A ₹17-crore GST demand coupled with steep margin deterioration creates a toxic mix of financial and regulatory stress. Investors should await GST response and Q2 results before re-engaging; the technical setup and cash-flow headwind argue for sidelines until visibility improves.
Informational and educational content only. Not investment advice.